Association of axon guidance factor Semaphorin 3A with poor outcome in pancreatic cancer


Mueller M. W. , Giese N. A. , Swiercz J. M. , Ceyhan G. , Esposito I., Hinz U., ...Daha Fazla

INTERNATIONAL JOURNAL OF CANCER, cilt.121, ss.2421-2433, 2007 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 121 Konu: 11
  • Basım Tarihi: 2007
  • Doi Numarası: 10.1002/ijc.22949
  • Dergi Adı: INTERNATIONAL JOURNAL OF CANCER
  • Sayfa Sayıları: ss.2421-2433

Özet

Neural alterations and aberrantly expressed nerve-specific factors promoting tumor progression are known to contribute to pancreatic cancer's extremely poor prognosis. Despite hints that axon guidance factor semaphorin 3A (SEMA3A) may function as a tumor inhibitor, its clinical importance and therapeutic potential have not yet been explored. The present study investigated the role of SEMA3A and its receptors-plexins A1-A4 (PLXNA1-A4) and neuropilin-1 (NRP1) - in pancreatic cancer. QRT-PCR and immunohistochemical analyses revealed overexpression of SEMA3A, NRP1 and PLXNA1 in metaplastic ducts, malignant cells and nerves of cancerous specimens, and showed that elevated levels of corresponding mRNA (6.8-fold, 2.0-fold and 1.5-fold, respectively) clearly correlated with negative clinicopathologic manifestations such as shorter survival (SEMA3A and PLXNA1) and a lesser degree of tumor differentiation (NRP1) in Stages I-III patients. High SEMA3A expression in pancreata of Stage IV M1 patients and in peritoneal metastases, and consequent functional studies indicated that poor clinical outcome might be related to the ability of SEMA3A to promote dissemination and invasiveness of pancreatic cancer cells through activation of multiple pathways involving Rac1, GSK3b or p42/p44 MAPK, but not E- to N-cadherin switch, MMP-9 or VEGF induction. Thus, this study is the first to quantify expression of the SEMA3A system in human malignancy and to show that overexpression of SEMA3A by nerves and transformed cells leads to a SEMA3A-rich environment which may favor malignant activities of tumor cells. Furthermore, negative clinicopathological correlations suggest that SEMA3A might represent a novel intervention target but not a treatment option for pancreatic cancer patients. (C) 2007 Wiley-Liss, Inc.